Amgen and Novartis are developing erenumab (AIMOVIG™, erenumab-aooe)-a fully 
human monoclonal antibody calcitonin gene-related peptide (CGRP) receptor 
antagonist-for the prevention of migraine. CGRP is a vasodilatory neuropeptide 
implicated in the pathophysiology of migraine and treatment with erenumab was 
associated with significant reductions in migraine frequency in phase II and III 
clinical trials. Based on these positive results erenumab was recently approved 
in the US for the preventive treatment of migraine in adults and has received a 
positive opinion in the EU for the prophylaxis of migraines in adults who have 
at least 4 migraine days per month. This article summarizes the milestones in 
the development of erenumab leading to this first approval.